Back to Search Start Over

Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study.

Authors :
Pecoraro A
Deuker M
Rosiello G
Stolzenbach F
Luzzago S
Tian Z
Shariat SF
Saad F
Briganti A
Kapoor A
Fiori C
Porpiglia F
Karakiewicz PI
Source :
Urologic oncology [Urol Oncol] 2021 Apr; Vol. 39 (4), pp. 239.e1-239.e7. Date of Electronic Publication: 2021 Feb 16.
Publication Year :
2021

Abstract

Background: The NCCN guidelines recommend active surveillance (AS) as an option for the initial management of cT1a 0-2 cm renal lesions. However, data about comparison between renal cell carcinoma (RCC) 0-2 cm vs. 2.1-4 cm are scarce.<br />Methods: Within the Surveillance, Epidemiology, and End Results database (2002-2016), 46,630 T1a N <subscript>any</subscript> M <subscript>any</subscript> stage patients treated with nephrectomy were identified. Data were tabulated according to histological subtype, tumor grade (low [LG] vs. high [HG]), as well as age category and gender. Additionally, rates of synchronous metastases were quantified.<br />Results: Overall, 69.3 vs. 74.1% clear cell, 21.4 vs. 17.6% papillary, 6.9 vs. 6.8% chromophobe, 2.0 vs. 1.1% sarcomatoid dedifferentiation, 0.2 vs. 0.2% collecting duct histological subtype were identified for respectively 0-2 cm and 2.1-4 cm RCCs. In both groups, advanced age was associated with higher rate of HG clear cell and HG papillary histological subtype. In 0-2 cm vs. 2.1-4 cm RCCs, 13.8% vs. 20.2% individuals operated on harbored HG tumors and were more prevalent in males. Lower synchronous metastases rates were recorded in 0-2 cm RCC and ranged from 0 in respectively multilocular cystic to 0.9% in HG papillary histological subtype. The highest synchronous metastases rates were recorded in sarcomatoid dedifferentiation histological subtype (13.8% and 9.7%) in both groups.<br />Conclusions: Relative to 2.1-4 cm RCCs, 0-2 cm RCCs harbored lower rates of HG tumors, lower rates of aggressive variant histology and lower rates of synchronous metastases. The indications and demographics of patients selected for AS may be expanded in the future to include younger and healthier patients.<br /> (Copyright © 2021. Published by Elsevier Inc.)

Details

Language :
English
ISSN :
1873-2496
Volume :
39
Issue :
4
Database :
MEDLINE
Journal :
Urologic oncology
Publication Type :
Academic Journal
Accession number :
33602621
Full Text :
https://doi.org/10.1016/j.urolonc.2021.01.003